Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Landon Johnson

Dermatology Wichita, KS Medical Doctor

NPI 1346478054 CMS profile 333563

1911 North Webb Rd, Wichita, KS 67206

Open in the dashboard

General payments

$5,641

290 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Landon Johnson of Wichita, KS is reported in the CMS Open Payments database as having received $5,641 across 290 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,117 58
2024 General $1,426 64
2023 General $767 37
2022 General $981 53
2021 General $596 42
2020 General $224 8
2019 General $529 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Landon Johnson
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Landon Johnson were reported at $1,117. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Landon Johnson Dermatology median Middle half National median
2019 $529 $454 $129–$1,240 $163
2020 $224 $235 $81–$756 $114
2021 $596 $377 $108–$1,108 $132
2022 $981 $514 $143–$1,391 $149
2023 $767 $607 $159–$1,674 $160
2024 $1,426 $751 $204–$1,903 $164
2025 $1,117 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,156 68 payments
  2. Janssen Biotech, Inc. $1,111 67 payments
  3. E.R. Squibb & Sons, L.L.C. $608 22 payments
  4. Novartis Pharmaceuticals Corporation $374 20 payments
  5. Lilly USA, LLC $359 17 payments
  6. Genzyme Corporation $329 13 payments
  7. Amgen Inc. $301 12 payments
  8. Pfizer Inc. $204 12 payments
  9. Sun Pharmaceutical Industries Inc. $203 11 payments
  10. Organogenesis Inc. $146 7 payments
  11. Other $849 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,479 288 payments
  2. Education $162 2 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $937 44 payments
  2. SOTYKTU $608 22 payments
  3. SKYRIZI $488 28 payments
  4. SIMPONI ARIA $362 33 payments
  5. STELARA $362 33 payments
  6. SIMPONI $362 33 payments
  7. TALTZ $340 16 payments
  8. HUMIRA $303 16 payments
  9. Otezla $301 12 payments
  10. DUPIXENT $259 10 payments
  11. Other $2,836 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,049

Median for Dermatology: 534

Drug cost

$9,522

Median for Dermatology: $67,151

Branded share of claims

12.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Monohydrate Generic 158 $2,823
Clobetasol Propionate Generic 42 $1,253
Metronidazole Generic 11 $679
Triamcinolone Acetonide Generic 107 $636
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 60 $614
Ketoconazole Generic 49 $535
Fluconazole Generic 40 $451
Clindamycin Phosphate Generic 18 $447
Cephalexin Generic 255 $401
Imiquimod Generic 17 $373

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$1,330,766

Of which drugs: $614,013

Medicare patients

1,921

Average age 76

Services billed

7,945

922 women, 999 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 38%
Ischemic heart disease 30%
Diabetes 24%
Atrial fibrillation 20%
Chronic kidney disease 19%
Depression 16%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $294
$294 — —
SKYRIZI
  • AbbVie, Inc. $226
$226 — —
TREMFYA
  • Janssen Biotech, Inc. $171
$171 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $72
$72 — —
Otezla
  • Amgen Inc. $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

290 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record